AmericaThe US Food and Drug Administration (FDA) has approved injectable HIV medications that last for a month instead of taking a daily pill.
A new drug called Cabenuva (including cabotegravir and rilpivirine) was approved by the FDA on January 21, making it more convenient for patients to treat HIV. Instead of remembering every day to take medicine and schedule meals, now only need to inject once a month. In addition, this new drug also creates more comfort for HIV patients.
“Medicines improve the quality of life for patients. They don’t want to be reminded of themselves every day as HIV positive,” said Dr. Steven Deeks, an HIV specialist at the University of California.
Cabotegravir and rilpivirine are packaged in two vials, given by injection. Bi-monthly doses are being tested.
The FDA also approved Vocabria (cabotegravir tablet) to be used in combination with rilpivirine for one month before starting parenteral therapy to ensure good tolerability.
The safety and efficacy of Cabenuva have been verified in two clinical trials involving 1,182 HIV-infected adults. Side effects with Cabenuva are injection site reaction, fever, fatigue, headache, musculoskeletal pain, nausea, sleep disturbances, dizziness, and rash.
Le Cam (According to the AP, FDA)